Federal government to fund hotline promoting abortion pill reversal
H.R. 796 — Second Chance for Moms Act · Filed by Mary Miller (R-IL) · 13 cosponsors · Introduced Jan 28, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires mifepristone (the abortion pill) to carry a warning label stating that its effects can allegedly be counteracted by natural progesterone, and directs the federal government to establish and fund a 24/7 hotline to refer women seeking to reverse mifepristone's effects to providers offering 'abortion pill reversal' services. The bill frames this as giving women a 'second chance' to continue pregnancy after taking the drug.
Why we flagged it
The bill's operative mechanism is not to restrict mifepristone access but to mandate a warning label promoting a specific medical countermeasure and to establish federal funding for a referral hotline directing women to providers of that service. This is functionally a government endorsement and subsidy of abortion-pill-reversal services.
What the text implies
- The warning label cites 'medical evidence' and the American Society for Reproductive Medicine regarding progesterone safety, but the bill does not require the label to disclose that major medical organizations (ACOG, ASRM itself in broader guidance) do not endorse mifepristone reversal as a standard-of-care intervention, creating a one-sided medical narrative.
- The hotline is restricted to referrals to 'APR providers only' — a narrow carve-out that excludes general OB/GYN practices, family medicine, or other providers, effectively creating a government-funded referral monopoly for a specific service sector.
The full analysis lists 4 implications of this text.
Who stands to gain
abortion pill reversal service providers; clinics offering mifepristone-reversal protocols